Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108288 | 0.84 | NPC1 (0.31) | — | |
| SCHEMBL26367236 | 0.81 | — | — | |
| SCHEMBL4191591 | 0.80 | CHRNB2 (0.34) | — | |
| SCHEMBL4186679 | 0.80 | CHRNB2 (0.34) | — | |
| SCHEMBL4191574 | 0.80 | CHRNB2 (0.34) | — | |
| SCHEMBL671359 | 0.80 | TP53 (0.42) | MEN1KMT2ATP53 | |
| SCHEMBL10709433 | 0.76 | TP53 (0.35) | MEN1KMT2ATP53 | |
| SCHEMBL10713567 | 0.76 | TP53 (0.35) | MEN1KMT2ATP53 | |
| SCHEMBL154677 | 0.75 | ALDH1A1 (0.41) | — | |
| SCHEMBL77528 | 0.75 | NAAA (0.39) | MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953861-B2 | Method of re-sensitizing vancomycin resistant bacteria which selectively cleave a cell wall depsipeptide | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2005-10-11 | — | — | US | disclosed |
| US-20040180814-A1 | Method for re-sensitizing vancomycin resistant bacteria which selectively cleave a cell wall depsipeptide | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE OF CITY OF NEWYORK | 2004-09-16 | — | — | US | disclosed |
| EP-1427435-A1 | METHOD FOR RE-SENSITIZING VANCOMYCIN RESISTANT BACTERIA USING AGENTS WHICH SELECTIVELY CLEAVE A CELL WALL DEPSIPEPTIDE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6734165-B2 | IN WHICH RESISTANCE RESULTS FROM CONVERSION OF AN AMIDE BOND TO AN ESTER BOND IN CELL WALL PEPTIDE PRECURSORS OF BACTERIA WHICH COMPRISES USING AN ANTIBACTERIAL AMOUNT OF VANCOMYCIN AND AN AGENT EFFECTIVE TO SELECTIVELY CLEAVE ESTER BOND | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2004-05-11 | — | — | US | disclosed |
| US-20030125372-A1 | Method for re-sensitizing vancomycin resistant bacteria which selectively cleave a cell wall depsipeptide | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-03 | — | — | US | disclosed |
| WO-2003035098-A1 | METHOD FOR RE-SENSITIZING VANCOMYCIN RESISTANT BACTERIA USING AGENTS WHICH SELECTIVELY CLEAVE A CELL WALL DEPSIPEPTIDE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY O F NEW YORK (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180814-A1 | Method for re-sensitizing vancomycin resistant bacteria which selectively cleave a cell wall depsipeptide | DNPEP, VIP, NRDC | MEN1 2874/4885KMT2A 3356/4885TP53 4334/4885 |
| US-20030125372-A1 | Method for re-sensitizing vancomycin resistant bacteria which selectively cleave a cell wall depsipeptide | DNPEP, VIP, NRDC | MEN1 2874/4885KMT2A 3356/4885TP53 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.